Firms Reach Cancer Drug Agreement
Times Staff and Wire Reports
Aphton Corp. said Rhone-Poulenc’s vaccines unit has agreed to pay it up to $10 million for the right to sell its experimental cancer drug, Gastrimmune. Under the agreement, Woodland Hills-based Aphton will be responsible for the development and clinical studies of the drug, which is being developed to treat patients with stomach, liver and pancreatic cancers. Pasteur Merieux, a unit of France’s Rhone-Poulenc, will sell the drug in the United States, Canada, Europe and Mexico.
